X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DISHMAN PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DISHMAN PHARMA SANOFI INDIA/
DISHMAN PHARMA
 
P/E (TTM) x 30.3 25.1 120.8% View Chart
P/BV x 5.4 3.3 159.9% View Chart
Dividend Yield % 1.7 0.7 253.7%  

Financials

 SANOFI INDIA   DISHMAN PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
DISHMAN PHARMA
Mar-16
SANOFI INDIA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs4,560374 1,217.9%   
Low Rs4,400129 3,413.5%   
Sales per share (Unadj.) Rs1,028.5197.8 520.0%  
Earnings per share (Unadj.) Rs129.021.2 608.1%  
Cash flow per share (Unadj.) Rs186.034.7 535.6%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.8 191.0%  
Book value per share (Unadj.) Rs753.6179.9 418.9%  
Shares outstanding (eoy) m23.0380.69 28.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.3 342.4%   
Avg P/E ratio x34.711.9 292.7%  
P/CF ratio (eoy) x24.17.2 332.4%  
Price / Book Value ratio x5.91.4 424.9%  
Dividend payout %52.79.4 559.1%   
Avg Mkt Cap Rs m103,17420,306 508.1%   
No. of employees `0003.60.8 437.0%   
Total wages/salary Rs m3,5925,355 67.1%   
Avg. sales/employee Rs Th6,537.719,252.7 34.0%   
Avg. wages/employee Rs Th991.46,459.5 15.3%   
Avg. net profit/employee Rs Th819.82,064.1 39.7%   
INCOME DATA
Net Sales Rs m23,68615,961 148.4%  
Other income Rs m708265 266.8%   
Total revenues Rs m24,39416,226 150.3%   
Gross profit Rs m5,2814,103 128.7%  
Depreciation Rs m1,3131,091 120.4%   
Interest Rs m15944 1.6%   
Profit before tax Rs m4,6612,334 199.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691624 271.2%   
Profit after tax Rs m2,9701,711 173.6%  
Gross profit margin %22.325.7 86.7%  
Effective tax rate %36.326.7 135.8%   
Net profit margin %12.510.7 117.0%  
BALANCE SHEET DATA
Current assets Rs m15,67311,018 142.3%   
Current liabilities Rs m6,6789,517 70.2%   
Net working cap to sales %38.09.4 403.8%  
Current ratio x2.31.2 202.7%  
Inventory Days Days76110 68.8%  
Debtors Days Days2235 64.1%  
Net fixed assets Rs m8,09816,304 49.7%   
Share capital Rs m230161 142.7%   
"Free" reserves Rs m17,08812,907 132.4%   
Net worth Rs m17,35614,516 119.6%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m25,40029,805 85.2%  
Interest coverage x311.73.5 8,981.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.5 174.1%   
Return on assets %11.88.9 131.9%  
Return on equity %17.111.8 145.2%  
Return on capital %26.917.5 153.7%  
Exports to sales %24.524.8 98.8%   
Imports to sales %28.03.7 748.9%   
Exports (fob) Rs m5,8013,956 146.6%   
Imports (cif) Rs m6,627596 1,111.4%   
Fx inflow Rs m7,1454,952 144.3%   
Fx outflow Rs m6,846697 982.5%   
Net fx Rs m2994,255 7.0%   
CASH FLOW
From Operations Rs m3,2262,786 115.8%  
From Investments Rs m-1,555-1,529 101.7%  
From Financial Activity Rs m-1,818-941 193.2%  
Net Cashflow Rs m-147316 -46.5%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 3.7 389.2%  
FIIs % 14.6 12.7 115.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 22.1 47.5%  
Shareholders   15,184 46,261 32.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ALEMBIC LTD  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 18, 2017 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS